MedXY
Not signed in Sign in / Register
Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • iDoctor
  • Medical Calculators
  • Videos
  • Health Games
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • iDoctor
  • Medical Calculators
  • Videos
  • Health Games

Sotagliflozin

  • Home
  • Sotagliflozin
Redefining Risk in Diabetic Kidney Disease: The 2022 AHA/ACC/HFSA Heart Failure Staging and the Efficacy of Sotagliflozin
Posted inClinical Updates Diabetes & Endocrinology news

Redefining Risk in Diabetic Kidney Disease: The 2022 AHA/ACC/HFSA Heart Failure Staging and the Efficacy of Sotagliflozin

Posted by By MedXY 03/20/2026
This review analyzes the prognostic value of the 2022 Heart Failure staging in patients with diabetes and kidney disease, highlighting the high risk of asymptomatic 'Pre-HF' and the consistent therapeutic benefits of sotagliflozin across all disease stages.
Read More

Take a game break

Explore a few games from MedXY.

Explore all games
  • Advancing Hair Loss Therapy: Sodium Citrate Enhances Comfort and Efficacy of Concentrated Growth Factor Treatment in Androgenetic Alopecia
  • Mitochondrial Dysfunction and Platelet Hyperactivation: A Novel Therapeutic Target in Sepsis
  • Assessing Cardiovascular Risk Prediction Models in Postmenopausal Women With Chronic Kidney Disease: Insights from the Women’s Health Initiative
  • Unraveling Donor Cell-Derived Hematologic Neoplasms: Insights from Spanish Transplant Centers
  • Targeting the Macrophage YTHDC1/TIGAR/NF-κB Axis: A Novel Therapeutic Strategy for Pulmonary Hypertension
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk case report chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology GLP-1 receptor agonists heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation machine learning MASLD mental health Mortality multiple myeloma myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prognosis public health quality of life randomized clinical trial randomized controlled trial risk stratification SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top